
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
TARBP2 (TARBP2 subunit of RISC loading complex) encodes an RNA-binding protein involved in RNA silencing pathways as a component of the RISC loading complex. It binds double-stranded RNA and participates in microRNA-mediated gene regulation and post-transcriptional control of gene expression.
Human cardiac ventricular cells are represented by AC16, an immortalized cell line derived from primary human ventricular tissue. The cells were generated by fusion of primary adult ventricular cardiomyocytes with a human fibroblast-like cell line carrying a temperature-sensitive SV40 large T antigen. AC16 exhibits cardiac-related characteristics and is used as an in vitro model for studies of human cardiomyocyte biology.
Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 2
Reference Transcript: NM_134323
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use






Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?